gdnf...it's back?
 

http://biotuesday.ca/2010/04/13/in-c...th-erich-mohr/
Conversation with Dr. Eric Mohr

His newest creation, closely held MedGenesis Therapeutix of Victoria, is making waves with a new treatment for serious neurologic diseases called convection-enhanced delivery (CED). Backed with a GDNF (glial cell line-derived neurotrophic factor) protein licensed from Amgen (NASDAQ:AMGN) and collaboration with Biovail (TSX:BVF; NYSE:BVF), MedGenesis and Biovail are tackling Parkinson’s disease. In this exclusive interview with BioTuesday.ca, Dr. Mohr explains the potential of CED and its potential to transform the practice of neurology and the treatment of neurologic diseases.

Last line of article:

"And the next largest shareholder is Andy Grove, the former chairman of Intel."

This one is going to be active I think. And in multiple platforms. They've been working and I am prepared to be awed....hope?:)